Debates between Baroness Bull and Baroness Barran during the 2017-2019 Parliament

Tue 18th Jun 2019

Folic Acid

Debate between Baroness Bull and Baroness Barran
Tuesday 18th June 2019

(4 years, 10 months ago)

Lords Chamber
Read Full debate Read Hansard Text
Baroness Barran Portrait Baroness Barran
- Hansard - - - Excerpts

The noble Baroness makes a helpful point. The consultation is available on GOV.UK, which I appreciate is not the most obvious place, but I say this in case noble Lords are interested in having a look at it. More seriously, the department is working closely with a number of charities and will have a big focus on social media in order to reach all the groups to which she referred. More broadly, as for industry stakeholders, the department is working with the Food and Drink Federation and the National Association of British and Irish Flour Millers.

Baroness Bull Portrait Baroness Bull (CB)
- Hansard - -

My Lords, notwithstanding the many positive impacts of fortification, concerns have been raised that increased levels of blood folate from fortification might impact the efficacy of anti-folate medication such as methotrexate, which works in chemotherapy by blocking the action of folic acid. In 2006 the SACN said that there was insufficient human data to say conclusively whether this is the case, and the 2017 SACN update makes no mention of anti-folates. Can the Minister reassure the House that there is now sufficient evidence to rule out conclusively any adverse impact of mandatory fortification on patients who are on methotrexate?

Baroness Barran Portrait Baroness Barran
- Hansard - - - Excerpts

I may need to write to the noble Baroness about the specific medication. More broadly, she is right that the Scientific Advisory Committee on Nutrition has looked at these issues. Also, Food Standards Scotland has updated the guidance. They support the mandatory inclusion of folic acid as long as it is combined with a reduction in the level of supplements such as those that exist in breakfast cereals. In the consultation the data is set out about the percentage of people whose intake might be above a tolerable threshold, and it is extremely low—between 0.5% and 1%.